CSIMarket
 
Coya Therapeutics Inc   (NASDAQ: COYA)
Other Ticker:  
 
 
Price: $5.6300 $0.00 0.000%
Day's High: $5.73 Week Perf: -1.4 %
Day's Low: $ 5.52 30 Day Perf: -6.94 %
Volume (M): 23 52 Wk High: $ 10.24
Volume (M$): $ 127 52 Wk Avg: $6.37
Open: $5.73 52 Wk Low: $4.65



 Market Capitalization (Millions $) 94
 Shares Outstanding (Millions) 17
 Employees 42
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Coya Therapeutics Inc
Coya Therapeutics Inc is a biotechnology company that focuses on developing innovative therapeutics for the treatment of cancer. They aim to address the challenges faced by conventional cancer therapies by utilizing a unique approach that combines multiple treatment modalities, such as targeted drugs, immunotherapies, and gene therapies.

The company's research and development efforts are centered around identifying and targeting specific cancer cell signaling pathways that play a crucial role in tumor growth and survival. By understanding the underlying mechanisms that drive cancer progression, Coya Therapeutics aims to develop novel therapies that can selectively and effectively target cancer cells while minimizing side effects on healthy tissues.

Coya Therapeutics also places a strong emphasis on precision medicine, utilizing advanced genomic technologies to identify specific genetic alterations in tumors that can be targeted with personalized therapies. This approach aims to tailor treatments to each patient's unique genetic profile, maximizing treatment efficacy and minimizing the risk of adverse events.

Overall, Coya Therapeutics Inc is dedicated to advancing the field of cancer therapeutics through innovative research and development, with the ultimate goal of improving patient outcomes and quality of life.


   Company Address: 5850 San Felipe St., Suite 500 Houston 77057 TX
   Company Phone Number: 587-8170   Stock Exchange / Ticker: NASDAQ COYA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY   -2.57%    
BMY   -2.57%    
REGN   -2.57%    
TEVA   -2.57%    
VRTX        1% 
VTRS        4.48% 
• View Complete Report
   



Business Update

Coya Therapeutics Demonstrates Promising Results in Alzheimer?s Disease with IL-2 Therapy Based on Inflammatory Blo...

Published Thu, Feb 6 2025 4:06 PM UTC

Houston-based Coya Therapeutics, Inc. a clinical-stage biotechnology company focusing on the enhancement of regulatory T cell (Treg) function, has announced promising results from a recent study evaluating low-dose interleukin-2 (LD IL-2) as a potential therapeutic approach for Alzheimer?s disease (AD). The company s announcement follows the completion of an investigator-ini...

Business Update

Coya Therapeutics, Inc. (NASDAQ COYA), a clinical-stage biotechnology firm focused on the devel...

Published Tue, Jan 21 2025 4:11 PM UTC

Title : Coya Therapeutics Expands Investigational Pipeline and Appoints New CEO to Drive Biologics Development for Inflammatory Diseases:Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology firm focused on the development of biologics that enhance regulatory T cell (Treg) function, has recently announced significant advancements in its investigational pipel...

Business Update

Catalysts for Change Coya Therapeutics Embarks on a New Leadership Journey

Published Tue, Nov 19 2024 1:47 PM UTC

In the ever-evolving landscape of biotechnology, leadership transitions can often signal significant changes in a company s strategic direction. Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech firm focused on enhancing regulatory T cell (Treg) function through innovative biologics, has recently undergone such a transition with the promotion of Dr. Arun Swami...

Business Update

Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics to enhance ...

Published Sat, Nov 2 2024 3:15 AM UTC

Coya Therapeutics Appoints Arun Swaminathan, Ph.D. as New CEO: A Strategic Move for Treg-Focused Biologics Development Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics to enhance regulatory T cell (Treg) function, has announced the promotion of Arun Swaminathan, Ph.D. to the position of Chief Executive Officer, effective November...

Business Update

Leadership Evolution and Market Momentum Coya Therapeutics Appoints Arun Swaminathan as CEO,

Published Fri, Nov 1 2024 3:36 PM UTC

Leadership Transition at Coya Therapeutics: An Update on Arun Swaminathan?s Appointment as CEO On November 1, 2024, Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology enterprise known for its pioneering work in biologics aimed at enhancing regulatory T cell (Treg) function, announced a significant change in its leadership structure. Arun Swaminathan, Ph.D...







Coya Therapeutics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com